ArticleTherapeutic advances in gastroenterology2025

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Shixian Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.